Merck: Merck's pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475AD77 trial

Merck, known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A─D77 phase 3 trial, evaluating the subcutaneous administration of pembrolizumab,